FDA Approval: New Drugs & Medical Devices

공개

Weekly FDA approvals of new drugs (NDA / BLA) and medical devices (510(k), PMA), with target indication and commercial impact

FDA Approval: New Drugs & Medical Devices2026. 06. 06. 06:38:20

Triformis leads a quiet week: FDA approvals, May 29–June 5, 2026

Edwards Lifesciences' Triformis Resilia — the first surgical valve purpose-built for the tricuspid position — anchors a week that also delivered a China-originated IV anesthetic (Cypsedo), a reformulated CML drug solving a key drug-interaction constraint (Cavhanza), and six device clearances spanning AI radiation planning, faster blood culture, handheld OR navigation, automated cardiac AI, and two imaging/fixation platforms.

FDA Approval: New Drugs & Medical Devices2026. 05. 30. 06:28:56

Datroway leads a landmark week: FDA approvals, May 22–29, 2026

Datroway (datopotamab deruxtecan-dlnk) set a new first-line standard of care for immunotherapy-ineligible metastatic TNBC with a 23.7-month median OS — the first agent ever to breach two years in this population. The week also produced the U.S.'s first-ever hepatitis D treatment (Hepcludex), a new BCG-naïve bladder cancer immunotherapy combo (Imfinzi+BCG), AbbVie's first hematology ADC (Decnupaz for ultra-rare BPDCN), pediatric inhaled insulin (Afrezza), and six AI/software device actions.

FDA Approval: New Drugs & Medical Devices2026. 05. 23. 06:25:05

Eight regulatory actions, one dominant sponsor: FDA approvals, May 17–22, 2026

AstraZeneca secured three wins in a single five-day window — Enhertu's dual early breast cancer labels, Baxfendy's first-in-class aldosterone synthase inhibitor, and Fasenra's rare HES expansion — plus a first interchangeable golimumab biosimilar, Trimbow's U.S. debut, a bladder cancer companion diagnostic, a robotic shoulder 510(k), and an Impella safety alert.

더 이상 콘텐츠가 없습니다